JP2022537515A5 - - Google Patents
Info
- Publication number
- JP2022537515A5 JP2022537515A5 JP2021573591A JP2021573591A JP2022537515A5 JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5 JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/090494 | 2019-06-10 | ||
| CN2019090494 | 2019-06-10 | ||
| PCT/CN2020/095354 WO2020249003A1 (en) | 2019-06-10 | 2020-06-10 | Antibody-interleukin fusion protein and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537515A JP2022537515A (ja) | 2022-08-26 |
| JP2022537515A5 true JP2022537515A5 (https=) | 2023-06-19 |
| JPWO2020249003A5 JPWO2020249003A5 (https=) | 2023-06-19 |
Family
ID=73781610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573591A Pending JP2022537515A (ja) | 2019-06-10 | 2020-06-10 | 抗体－インターロイキン融合タンパク質および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220306713A1 (https=) |
| EP (1) | EP3980067A4 (https=) |
| JP (1) | JP2022537515A (https=) |
| CN (1) | CN114599390A (https=) |
| CA (1) | CA3143218A1 (https=) |
| WO (1) | WO2020249003A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4126965A4 (en) * | 2020-05-14 | 2024-10-02 | Elixiron Immunotherapeutics (Hong Kong) Limited | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS |
| IL305758A (en) * | 2021-03-10 | 2023-11-01 | Immunowake Inc | Immunomodulatory compounds and their uses |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| CN118434759A (zh) * | 2021-10-10 | 2024-08-02 | 安立玺荣生医(香港)有限公司 | 用抗-pd-l1/il-10融合蛋白治疗疾病的方法 |
| WO2023078245A1 (zh) * | 2021-11-02 | 2023-05-11 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| CN116063547A (zh) * | 2022-07-08 | 2023-05-05 | 盛禾(中国)生物制药有限公司 | 一种二聚体融合蛋白及其应用 |
| WO2024131864A1 (zh) * | 2022-12-21 | 2024-06-27 | 广东菲鹏制药股份有限公司 | 一种il-10单体融合蛋白 |
| WO2025077212A1 (zh) * | 2023-10-08 | 2025-04-17 | 广东菲鹏制药股份有限公司 | 抗pd1-il10融合蛋白及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592420A (en) * | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| EP3068425B1 (en) * | 2013-11-11 | 2021-01-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| CA3079844A1 (en) * | 2017-11-10 | 2019-05-16 | Armo Biosciences, Inc. | Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors |
-
2020
- 2020-06-10 WO PCT/CN2020/095354 patent/WO2020249003A1/en not_active Ceased
- 2020-06-10 JP JP2021573591A patent/JP2022537515A/ja active Pending
- 2020-06-10 CN CN202080055588.4A patent/CN114599390A/zh active Pending
- 2020-06-10 CA CA3143218A patent/CA3143218A1/en active Pending
- 2020-06-10 EP EP20822767.8A patent/EP3980067A4/en not_active Withdrawn
- 2020-06-10 US US17/617,945 patent/US20220306713A1/en not_active Abandoned